Cartesian Therapeutics, Inc.
RNAC
Kedudukan dalam Saham
#18421
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.27
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$189.70M
Perubahan (1 hari)
-4.71%
Perubahan (1 tahun)
839.61%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Modal pasaran bagi Cartesian Therapeutics, Inc.(RNAC)
Modal Pasaran: $189.70M
Sehingga October 2026, Cartesian Therapeutics, Inc. mempunyai modal pasaran sebanyak $189.70M. Ini menjadikan Cartesian Therapeutics, Inc. syarikat ke-18421st paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Cartesian Therapeutics, Inc. dari 2016 hingga 2026
RNAC berbanding dengan 5 teratas yang paling popular stocks
